Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

2.855 -0.065 (-2.23%)
Streaming Delayed Price Updated: 11:13 AM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
What's Going On With MannKind Stock Friday? ↗
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations. 
Via Benzinga
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 ↗
Via Chartmill
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
Via Stocktwits
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
Via Stocktwits
News headline image
Why MannKind Stock Tumbled on Thursday ↗
Mr. Market was hoping for a better fourth quarter than the company delivered. 
Via The Motley Fool
News headline image
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ ↗
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.” 
Via Stocktwits
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
Via Stocktwits
Here are the top movers in Wednesday's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D 
From MannKind
Via GlobeNewswire
News headline image
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? ↗
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus. 
Via Stocktwits
News headline image
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
From MannKind
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
MannKind Provides Business Updates and 2026 Growth Drivers
From MannKind
Via GlobeNewswire
News headline image
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
MannKind Shares FUROSCIX® Business Updates
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at the Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.